05 January 2019 | News
Prior to Roche, he held positions of increasing responsibility at BioMarin Pharmaceutical, Inc, where he most recently served as Senior Vice President of Product Development
US based biotech company, Tizona Therapeutics has announced that Scott Clarke has joined the company as its chief executive officer. Clarke joins from Roche where he served as the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering.
Also, the company announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for its lead drug candidate, TTX-030, a first-in-class CD39-targeting immunotherapy for the treatment of cancer. In addition to TTX-030, Tizona has a portfolio of novel immuno-oncology product candidates in discovery and advanced pre-clinical development.
The ATP/adenosine axis has recently emerged as a key immune regulatory switch in the tumor microenvironment. Inhibition of CD39 with TTX-030 represents a novel and differentiated approach to targeting this pathway.
Luke Evnin, Chairman of Tizona’s Board of Directors said, “We are thrilled to bring Scott on as CEO during this critical time for Tizona as it transitions to a clinical stage company. Scott has a stellar track record as a leader and extensive experience in both partnering and product development. Importantly, he shares our vision for delivering next generation immunotherapies to patients.”
“Tizona is poised to become a leading player in developing immunotherapies that target immune suppression, evasion and escape. I’m honored to join Tizona’s high caliber leadership team in fulfilling this mission”, he added.
While at Roche, Clarke was responsible for worldwide oncology partnering activities, including identifying and evaluating product and company acquisition opportunities, and structuring and negotiating collaborations and licenses.
Prior to Roche, he held positions of increasing responsibility at BioMarin Pharmaceutical, Inc, where he most recently served as Senior Vice President of Product Development. He earned a Bachelor of Science in Chemical Engineering from the University of California, Berkeley, a Master of Science in Biotechnology at Northwestern University and an MBA at London Business School.